StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO – Free Report) in a report released on Tuesday morning. The firm issued a hold rating on the stock.
A number of other research firms also recently weighed in on EKSO. Lake Street Capital started coverage on Ekso Bionics in a research note on Monday, June 24th. They issued a buy rating and a $2.50 price target on the stock. HC Wainwright raised their target price on Ekso Bionics from $9.25 to $10.00 and gave the stock a buy rating in a report on Tuesday, April 30th.
Check Out Our Latest Research Report on EKSO
Ekso Bionics Stock Performance
Ekso Bionics (NASDAQ:EKSO – Get Free Report) last issued its quarterly earnings results on Monday, July 29th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The company had revenue of $4.95 million during the quarter, compared to analyst estimates of $5.34 million. Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. During the same period in the prior year, the business earned ($0.31) EPS. On average, equities research analysts predict that Ekso Bionics will post -0.42 EPS for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Ekso Bionics stock. Kent Lake Capital LLC acquired a new stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 141,158 shares of the company’s stock, valued at approximately $353,000. Kent Lake Capital LLC owned 0.95% of Ekso Bionics as of its most recent filing with the SEC. 6.42% of the stock is owned by institutional investors.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
Featured Stories
- Five stocks we like better than Ekso Bionics
- Options Trading – Understanding Strike Price
- Should You Invest in Bitcoin? Pros and Cons
- Why is the Ex-Dividend Date Significant to Investors?
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- Profitably Trade Stocks at 52-Week Highs
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.